Eloxx Pharmaceuticals, Inc. Total Assets
Eloxx Pharmaceuticals, Inc. total assets. Based on the latest financial reports, Eloxx Pharmaceuticals, Inc. (ELOX) holds total assets worth $63.39 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Eloxx Pharmaceuticals, Inc. for the company's overall valuation and market capitalisation.
Total Assets of Eloxx Pharmaceuticals, Inc. (2004–2025)
Total assets of Eloxx Pharmaceuticals, Inc. from 2004 to 2025. This chart illustrates how Eloxx Pharmaceuticals, Inc.'s total assets have evolved over time, based on quarterly financial data. See Eloxx Pharmaceuticals, Inc. stock quote for real-time trading data and today's change.
Eloxx Pharmaceuticals, Inc. - Asset Composition Analysis
Eloxx Pharmaceuticals, Inc. Total Assets Breakdown (December 2025)
Eloxx Pharmaceuticals, Inc. total assets breakdown as of December 2025. Eloxx Pharmaceuticals, Inc.'s total assets of $63.39 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Eloxx Pharmaceuticals, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Eloxx Pharmaceuticals, Inc. short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eloxx Pharmaceuticals, Inc.'s current assets represent 100.0% of total assets in 2025, an increase from 81.2% in 2004.
- Cash Position: Cash and equivalents constituted 90.9% of total assets in 2025, up from 3.6% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Eloxx Pharmaceuticals, Inc. Competitors by Total Assets
Key competitors of Eloxx Pharmaceuticals, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Eloxx Pharmaceuticals, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.74 | 0.33 | 3.85 |
| Quick Ratio | 3.74 | 0.33 | 3.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $46.42 Million | $-13.06 Million | $43.35 Million |
Eloxx Pharmaceuticals, Inc. - Advanced Valuation Insights
This section examines the relationship between Eloxx Pharmaceuticals, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 10.30 |
| Asset Growth Rate (YoY) | 77.1% |
| Total Assets | $5.27 Million |
| Market Capitalization | $54.29 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Eloxx Pharmaceuticals, Inc.'s assets at a significant premium (10.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Eloxx Pharmaceuticals, Inc.'s assets grew by 77.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eloxx Pharmaceuticals, Inc. (2004–2025)
The table below shows the annual total assets of Eloxx Pharmaceuticals, Inc. from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.27 Million | +77.08% |
| 2024-12-31 | $2.98 Million | +73.83% |
| 2023-12-31 | $1.71 Million | -91.90% |
| 2022-12-31 | $21.12 Million | -53.20% |
| 2021-12-31 | $45.14 Million | +70.48% |
| 2020-12-31 | $26.48 Million | -55.08% |
| 2019-12-31 | $58.95 Million | +16.23% |
| 2018-12-31 | $50.72 Million | +104.64% |
| 2017-12-31 | $24.78 Million | +168.63% |
| 2016-12-31 | $9.23 Million | -52.80% |
| 2015-12-31 | $19.55 Million | -41.36% |
| 2014-12-31 | $33.33 Million | +369.65% |
| 2013-12-31 | $7.10 Million | +2.05% |
| 2012-12-31 | $6.95 Million | -19.10% |
| 2011-12-31 | $8.60 Million | -38.20% |
| 2010-12-31 | $13.91 Million | +95.32% |
| 2009-12-31 | $7.12 Million | -33.08% |
| 2008-12-31 | $10.64 Million | +220.40% |
| 2007-12-31 | $3.32 Million | -6.04% |
| 2006-12-31 | $3.54 Million | -42.17% |
| 2005-12-31 | $6.11 Million | +17.31% |
| 2004-12-31 | $5.21 Million | -- |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney dis… Read more